Takeda’s Millennium Seeks Modest Acquisitions, But Could Go Bigger
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical has freed its U.S.-based Millennium biotech unit to seek its own mergers and acquisitions among the more modest players in the drug making industry. CEO Deborah Dunshire said in an interview that Millennium is not likely to try to acquire a large company, noting Takeda's own avoidance of such deals. She said a Millennium M&A is likely to center on "smaller, single-product acquisitions." She did not, however, rule out a larger transaction as big as the $10 billion range. (Click here for more - a subscription may be required